clinical trial · NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Advanced Solid TumorOvarian CancerOvarian Clear Cell CarcinomaOvarian Clear Cell TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Endometrioid TumorARID1A Gene MutationNXP800
brief summary
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
started
Dec 31, 2021
primary completion
Dec 1, 2025
completion
Dec 1, 2025
last updated
Aug 8, 2025
detailed description
Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies.
In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol